Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.25

-0.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

keokalani'nui

To: Miljenko Zuanic who wrote (2677)	4/8/2019 6:16:40 PM
From: Miljenko Zuanic	1 Recommendation Read Replies (2) of 3557

One may premature conclude that ALNY/REGN ophthalmology (as part) collaboration negate REGN/ADMV ocular gene therapy efforts. Contrary, it may be opposite (nonetheless both options are equally possible). siRNA is method of silencing protein transcription/expression (agonist or antagonist), while gene therapy is to enhance protein expressions (which also may be agonist or antagonist). So, ALNY/REGN alliance may be INDEPENDENT step forward from ADVM collaborations, but also additional step in broad ophthalmology efforts! I continue to be cautious optimistic with ADVM AAV program.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next